Journal article

Leptin Mediates the Increase in Blood Pressure Associated with Obesity

Stephanie E Simonds, Jack T Pryor, Eric Ravussin, Frank L Greenway, Ralph Dileone, Andrew M Allen, Jaspreet Bassi, Joel K Elmquist, Julia M Keogh, Elana Henning, Martin G Myers, Julio Licinio, Russell D Brown, Pablo J Enriori, Stephen O'Rahilly, Scott M Sternson, Kevin L Grove, David C Spanswick, I Sadaf Farooqi, Michael A Cowley

CELL | CELL PRESS | Published : 2014

Grants

Awarded by National Health and Medical Research Council of Australia


Awarded by NORC Center grant at the Pennington Biomedical Research Center


Awarded by Wellcome Trust


Awarded by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES


Awarded by Medical Research Council


Awarded by National Institute for Health Research


Funding Acknowledgements

This work was supported by the Heart Foundation of Australia (M.A.C. and S.E.S.), the National Health and Medical Research Council of Australia (1029188 to M.A.C. and 1063955 to D.C.S.), Monash University (S.E.S.), Pfizer Australia (M.A.C.), a NORC Center grant (P30DK072476) at the Pennington Biomedical Research Center (E.R., F.L.G., and J.L.), the Leverhulme Trust (J.T.P.), the Wellcome Trust (082390/Z/07/Z) (I.S.F.), Medical Research Council (I.S.F.), NIHR Cambridge Biomedical Research Centre (I.S.F. and S.O.R.), and the Bernard Wolfe Health Neuroscience Fund (I.S.F.). We thank Professor Streamson Chua for the LepR flox mice. J.L. and I.S.F. treat patients with recombinant human leptin which is provided by BMS/AstraZeneca.